| 2023-08-01 |
复牌提示：
2023-07-31 19:50:09 停牌，复牌日期 2023-08-02 00:00:01
|
| 2023-06-15 |
股东大会：
将于2023-07-27召开股东大会
会议内容 ▼▲
- 1.To vote on a proposal to adopt the Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”), a copy of which is attached as Annex A to the enclosed joint proxy statement/prospectus (the “Spectrum merger proposal”);
2.To vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid to Spectrum’s named executive officers in connection with the Merger (as defined below) (the “Spectrum advisory compensation proposal”);
3.To vote on a proposal to approve the adjournment of the Spectrum special meeting to solicit additional proxies if there are not sufficient votes cast at the Spectrum special meeting to approve the Spectrum merger proposal or to ensure that any supplemental or amended disclosure, including any supplement or amendment to the enclosed joint proxy statement/prospectus, is timely provided to Spectrum stockholders (the “Spectrum adjournment proposal”).
|
| 2023-06-15 |
详情>>
股本变动：
变动后总股本20524.57万股
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.02美元,归母净利润-500.7万美元,同比去年增长67.58%
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-0.41美元,归母净利润-7540.1万美元,同比去年增长52.47%
|
| 2023-03-22 |
财报披露：
美东时间 2023-03-22 盘前发布财报
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.37美元,归母净利润-6641.5万美元,同比去年增长44.15%
|
| 2022-08-12 |
详情>>
业绩披露：
2022年中报每股收益-0.26美元,归母净利润-4449万美元,同比去年增长48.16%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.09美元,归母净利润-1544.2万美元,同比去年增长56.74%
|
| 2022-04-27 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.To elect the six director nominees named in the Proxy Statement to serve until our Annual Meeting to be held in 2023, or until their successors are duly elected and qualified.
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.To approve the adoption of a proposed amended and restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.
4.To ratify the selection of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
5.To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2022-03-18 |
详情>>
业绩披露：
2021年年报每股收益-1.02美元,归母净利润-1.59亿美元,同比去年增长1.39%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.78美元,归母净利润-1.19亿美元,同比去年增长1.81%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-12 |
详情>>
业绩披露：
2021年中报每股收益-0.57美元,归母净利润-8582.9万美元,同比去年增长-18.13%
|
| 2021-05-13 |
详情>>
业绩披露：
2021年一季报每股收益-0.25美元,归母净利润-3569.7万美元,同比去年增长12.02%
|
| 2021-04-21 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the seven director nominees named in the Proxy Statement to serve until our Annual Meeting to be held in 2022, or until their successors are duly electedand qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
4.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2021-03-31 |
详情>>
业绩披露：
2020年年报每股收益-1.29美元,归母净利润-1.61亿美元,同比去年增长-42.75%
|
| 2020-04-22 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the seven director nominees named in the Proxy Statement to serve until our Annual Meeting to be held in 2021, or until their successors are duly elected and qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
4.Amendment to the 2018 Long-Term Incentive Plan. To approve the adoption of a proposed Amendment to the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.
5.Ratification of Selection of Independent Registered Public Accounting Firm.
6.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
7.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2019-04-23 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the seven director nominees named in the Proxy Statement to serve until our Annual Meeting to be held in 2020, or until their successors are duly elected and qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
4.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2018-06-25 |
详情>>
内部人交易：
Riga Thomas J股份减少235.00股
|
| 2018-05-07 |
股东大会：
将于2018-06-18召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the eight directors named in the Proxy Statement to serve until our Annual Meeting to be held in 2019, or until their successors are duly elected and qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.Amendment and Restatement of our Certificate of Incorporation, as amended. To approve an amendment and restatement of our Certificate of Incorporation, as amended, to (i) increase the number of authorized shares of our common stock, par value $0.001 per share, from 175,000,000 to 300,000,000; (ii) increase the number of authorized shares of our capital stock from 180,000,000 to 305,000,000, with no effect on our 5,000,000 authorized shares of preferred stock; and (iii) eliminate our designated series of preferred stock that are no longer outstanding or issuable.
4.2018 Long-Term Incentive Plan. To approve the adoption of the proposed Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.
5.Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
6.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2017-04-17 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the seven directors named in the Proxy Statement to serve until our Annual Meeting to be held in 2018, or until their successors are elected and duly qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.Advisory Vote on the Frequency of an Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, how frequently we should seek from our stockholders a non-binding advisory vote on the compensation of our named executive officers.
4.Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
5.Stockholder Proposal Regarding Majority Voting Standard. To vote on a stockholder proposal regarding a majority voting standard in uncontested elections of directors, if properly presented at the 2017 Annual Meeting.
6.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-28召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect seven directors to serve until our Annual Meeting to be held in 2017, or until their successors are elected and duly qualified.
2.Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
3.Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
4.Stockholder Proposal regarding Proxy Access. To vote on a stockholder proposal regarding proxy access, if properly presented at the 2016 Annual Meeting.
5.Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2015-04-30 |
股东大会：
将于2015-06-29召开股东大会
会议内容 ▼▲
- 1. Election of Directors. To elect seven directors to serve until our Annual Meeting of Stockholders to be held in 2016, or until their successors are elected and duly qualified.
2. Approval of Flexible Settlement Feature for the Potential Conversion of Convertible Senior Notes. To approve the flexible settlement feature in connection with the potential conversion of our Convertible Senior Notes, which would allow us to settle the conversion of the Notes, at our option, with shares of our common stock and/or their equivalent cash value at the time of conversion.
3. Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
4. Advisory Vote on the Compensation of Our Named Executive Officers. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
5. Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2014-04-29 |
股东大会：
将于2014-06-27召开股东大会
会议内容 ▼▲
- 1. Election of Directors. To elect seven directors to serve until our Annual Meeting of Stockholders to be held in 2015, or until their successors are elected and duly qualified.
2. Approval of Flexible Settlement Feature for the Potential Conversion of Convertible Senior Notes. To approve the flexible settlement feature in connection with the potential conversion of our Convertible Senior Notes, which could result in the issuance of an aggregate amount of shares of our common stock equal to 20% or more of the amount of outstanding common stock at the time the Convertible Senior Notes were priced.
3. Ratification of Selection of Independent Registered Public Accounting Firm. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
4. Advisory Vote on the Compensation of Our Named Executive Officers. To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
5. Other Business. To consider and act upon such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.
|
| 2012-12-10 |
除权日：
美东时间 2012-12-18 每股派息0.15美元
|